How High Will Brown Forman Stock Go?
On the surface, Brown‑Forman (NYSE: BF.B) is having an unremarkable year.…
Sell
24
IDYA Quote, Financials, Valuation and Earnings
Last price:
$21.59
Seasonality move
:
-2.5%
Day range:
$21.56 - $22.56
52-week range:
$13.45 - $44.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
67.60x
P/B ratio:
1.85x
Volume:
549.7K
Avg. volume:
963.9K
1-year change:
-47.48%
Market cap:
$1.9B
Revenue:
$7M
EPS (TTM):
-$3.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences
|
$3.8M | -$0.80 | 9.84% | -16.36% | $46.93 |
|
ELAN
Elanco Animal Health
|
$1.2B | $0.20 | 0.16% | 407.4% | $15.45 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences
|
$21.59 | $46.93 | $1.9B | -- | $0.00 | 0% | 67.60x |
|
ELAN
Elanco Animal Health
|
$14.78 | $15.45 | $7.3B | 19.97x | $0.00 | 0% | 1.66x |
|
NBY
NovaBay Pharmaceuticals
|
$0.66 | $0.85 | $3.9M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.68 | -- | $27M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.35 | $1.00 | $966.3K | -- | $0.00 | 0% | 0.43x |
|
TOVX
Theriva Biologics
|
$0.48 | $7.00 | $4M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences
|
-- | 1.048 | -- | 14.68x |
|
ELAN
Elanco Animal Health
|
40.89% | 2.904 | 84.31% | 1.22x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences
|
-- | -$84.4M | -29.19% | -29.19% | -2059.11% | -$61.7M |
|
ELAN
Elanco Animal Health
|
$684M | $121M | 3.36% | 6.02% | 8.38% | -$69M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
IDEAYA Biosciences vs. Competitors
-
Which has Higher Returns IDYA or ELAN?
Elanco Animal Health has a net margin of -1861.6% compared to IDEAYA Biosciences's net margin of 5.62%. IDEAYA Biosciences's return on equity of -29.19% beat Elanco Animal Health's return on equity of 6.02%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences-- -$0.82 $1.1B ELANElanco Animal Health57.34% $0.13 $10.7B -
What do Analysts Say About IDYA or ELAN?
IDEAYA Biosciences has a consensus price target of $46.93, signalling upside risk potential of 117.36%. On the other hand Elanco Animal Health has an analysts' consensus of $15.45 which suggests that it could grow by 4.56%. Given that IDEAYA Biosciences has higher upside potential than Elanco Animal Health, analysts believe IDEAYA Biosciences is more attractive than Elanco Animal Health.
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences11 2 0 ELANElanco Animal Health8 6 0 -
Is IDYA or ELAN More Risky?
IDEAYA Biosciences has a beta of 0.035, which suggesting that the stock is 96.549% less volatile than S&P 500. In comparison Elanco Animal Health has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.489%.
-
Which is a Better Dividend Stock IDYA or ELAN?
IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elanco Animal Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Elanco Animal Health pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or ELAN?
IDEAYA Biosciences quarterly revenues are $7M, which are smaller than Elanco Animal Health quarterly revenues of $1.2B. IDEAYA Biosciences's net income of -$71.4M is lower than Elanco Animal Health's net income of $67M. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Elanco Animal Health's PE ratio is 19.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 67.60x versus 1.66x for Elanco Animal Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences67.60x -- $7M -$71.4M ELANElanco Animal Health1.66x 19.97x $1.2B $67M
-
Which has Higher Returns IDYA or NBY?
NovaBay Pharmaceuticals has a net margin of -1861.6% compared to IDEAYA Biosciences's net margin of -49.65%. IDEAYA Biosciences's return on equity of -29.19% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences-- -$0.82 $1.1B NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About IDYA or NBY?
IDEAYA Biosciences has a consensus price target of $46.93, signalling upside risk potential of 117.36%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 28.21%. Given that IDEAYA Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe IDEAYA Biosciences is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences11 2 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is IDYA or NBY More Risky?
IDEAYA Biosciences has a beta of 0.035, which suggesting that the stock is 96.549% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock IDYA or NBY?
IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or NBY?
IDEAYA Biosciences quarterly revenues are $7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IDEAYA Biosciences's net income of -$71.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 67.60x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences67.60x -- $7M -$71.4M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns IDYA or NNVC?
Nanoviricides has a net margin of -1861.6% compared to IDEAYA Biosciences's net margin of --. IDEAYA Biosciences's return on equity of -29.19% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences-- -$0.82 $1.1B NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About IDYA or NNVC?
IDEAYA Biosciences has a consensus price target of $46.93, signalling upside risk potential of 117.36%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 286.91%. Given that Nanoviricides has higher upside potential than IDEAYA Biosciences, analysts believe Nanoviricides is more attractive than IDEAYA Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences11 2 0 NNVCNanoviricides0 0 0 -
Is IDYA or NNVC More Risky?
IDEAYA Biosciences has a beta of 0.035, which suggesting that the stock is 96.549% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock IDYA or NNVC?
IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or NNVC?
IDEAYA Biosciences quarterly revenues are $7M, which are larger than Nanoviricides quarterly revenues of --. IDEAYA Biosciences's net income of -$71.4M is lower than Nanoviricides's net income of -$2.2M. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 67.60x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences67.60x -- $7M -$71.4M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns IDYA or OGEN?
Oragenics has a net margin of -1861.6% compared to IDEAYA Biosciences's net margin of --. IDEAYA Biosciences's return on equity of -29.19% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences-- -$0.82 $1.1B OGENOragenics-- -$3.60 -- -
What do Analysts Say About IDYA or OGEN?
IDEAYA Biosciences has a consensus price target of $46.93, signalling upside risk potential of 117.36%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2122.44%. Given that Oragenics has higher upside potential than IDEAYA Biosciences, analysts believe Oragenics is more attractive than IDEAYA Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences11 2 0 OGENOragenics0 1 0 -
Is IDYA or OGEN More Risky?
IDEAYA Biosciences has a beta of 0.035, which suggesting that the stock is 96.549% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock IDYA or OGEN?
IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or OGEN?
IDEAYA Biosciences quarterly revenues are $7M, which are larger than Oragenics quarterly revenues of --. IDEAYA Biosciences's net income of -$71.4M is lower than Oragenics's net income of -$2.2M. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 67.60x versus 0.43x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences67.60x -- $7M -$71.4M OGENOragenics0.43x -- -- -$2.2M
-
Which has Higher Returns IDYA or TOVX?
Theriva Biologics has a net margin of -1861.6% compared to IDEAYA Biosciences's net margin of --. IDEAYA Biosciences's return on equity of -29.19% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences-- -$0.82 $1.1B TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About IDYA or TOVX?
IDEAYA Biosciences has a consensus price target of $46.93, signalling upside risk potential of 117.36%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1349.28%. Given that Theriva Biologics has higher upside potential than IDEAYA Biosciences, analysts believe Theriva Biologics is more attractive than IDEAYA Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences11 2 0 TOVXTheriva Biologics1 1 0 -
Is IDYA or TOVX More Risky?
IDEAYA Biosciences has a beta of 0.035, which suggesting that the stock is 96.549% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock IDYA or TOVX?
IDEAYA Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or TOVX?
IDEAYA Biosciences quarterly revenues are $7M, which are larger than Theriva Biologics quarterly revenues of --. IDEAYA Biosciences's net income of -$71.4M is lower than Theriva Biologics's net income of -$4.3M. Notably, IDEAYA Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences is 67.60x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences67.60x -- $7M -$71.4M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
TLN alert for Jul 19
Talen Energy [TLN] is up 24.44% over the past day.
Sell
48
CRSP alert for Jul 19
CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.
Buy
83
SOC alert for Jul 19
Sable Offshore [SOC] is up 11.86% over the past day.
